Name | ajmalicine hydrochloride |
---|---|
Synonyms |
Circolene
Pytetrahydroserpentine Einecs 224-471-9 d-Yohimbine δ-Yohimbine RAUBASINE HYDROCHLORIDE AJMALICINE HCL (19α)-16,17-Didehydro-19-methyl-oxayohimban-16-carboxylic acid methyl ester Methyl (19α)-19-methyl-16,17-didehydro-18-oxayohimban-16-carboxylate Methyl (4S,4aR,13bS,14aS)-4-methyl-4a,5,7,8,13,13b,14,14a-octahydro-4H-indolo[2,3-a]pyrano[3,4-g]quinolizine-1-carboxylate Raubasine Ajmalicine ajmalicine,monohydrochloride Oxayohimban-16-carboxylic acid, 16,17-didehydro-19-methyl-, methyl ester, (19α)- Lamuran Methyl-(4S,4aR,13bS,14aS)-4-methyl-4a,5,7,8,13,13b,14,14a-octahydro-4H-indolo[2,3-a]pyrano[3,4-g]chinolizin-1-carboxylat Methyl-(19α)-19-methyl-16,17-didehydro-18-oxayohimban-16-carboxylat AJMALICIN HCL Tetrahydroserpentine |
Description | Ajmalicine (Raubasine) hydrochloride is a potent adrenolytic agent which preferentially blocks α1-adrenoceptor. Ajmalicine hydrochloride is an reversible but non-competitive nicotine receptor full inhibitor, with an IC50 of 72.3 μM. Ajmalicine hydrochloride also can be used as anti-hypertensive, and serpentine, with sedative activity[1][2]. |
---|---|
Related Catalog | |
Target |
α1-adrenergic receptor α2-adrenergic receptor |
In Vitro | Ajmalicine hydrochloride preferentially blocks α1-adrenoceptor than α2-adrenoceptor[1]. Ajmalicine hydrochloride inhibits contractions in a concentration-dependent manner (IC50=72.3 ± 22.5 μM)[2]. Ajmalicine hydrochloride acts preferentially at postsynaptic sites, competitively antagonizes the effect of noradrenaline on postsynaptic alpha-adrenoceptor with a pA2 value of 6.57, blocks the inhibitory effect of clonidine with an pA2 value of 6.2[3]. |
In Vivo | Ajmalicine hydrochloride blocking the pressor action of electrical stimulation and is active against sympathetic stimulation[1]. Ajmalicine hydrochloride (0.5-4 mg/kg) induces a marked dose-dependent inhibition against the pressor response to noradrenaline[1]. Animal Model: Male Wistar rats (300-350 g)[1] Dosage: 0.5, 1, 2, and 4 mg/kg Administration: IV, once Result: Induced a marked dose-dependent inhibition against the pressor response to noradrenaline. |
References |
Density | 1.3±0.1 g/cm3 |
---|---|
Boiling Point | 524.0±50.0 °C at 760 mmHg |
Melting Point | 275-300ºC |
Molecular Formula | C21H24N2O3 |
Molecular Weight | 352.427 |
Flash Point | 270.7±30.1 °C |
Exact Mass | 352.178680 |
PSA | 54.56000 |
LogP | 2.88 |
Vapour Pressure | 0.0±1.4 mmHg at 25°C |
Index of Refraction | 1.656 |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
Hazard Codes | Xn |
---|---|
Risk Phrases | 22-36/37/38 |
Safety Phrases | 26-36 |
WGK Germany | 3 |
RTECS | AX7890000 |